Dienstag, 02. Oktober 2018

PARI Pharma’s eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed’s ARIKAYCE® (amikacin liposome inhalation suspension).

ARIKAYCE is the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients...
Donnerstag, 07. Dezember 2017

MagnairTM an eFlow® Closed System Nebulizer together with Sunovion’s LonhalaTM is the first eFlow technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD

LONHALA MAGNAIR Inhalation Solution is the first nebulized long-acting muscarinic antagonist (LAMA) approved for the treatment of COPD in the U.S.
Freitag, 08. September 2017

New Treatment in Nontuberculous Mycobacterial Lung Disease seams possible

Insmed announces positive phase III results with ALIS and eFlow®
Donnerstag, 30. März 2017

Immunsuppressivum nach Lungentransplantation via eFlow-Technologie

PARI Pharma lizensiert Rechte an inhalativem Cyclosporine-A an Breath Therapeutics
Mittwoch, 02. November 2016

Sunovion Announces FDA Filing Acceptance of New Drug Application for Sun-101/eFlow® for the Treatment of Patients with Chronic Obstuctive Pulmonary Disease (COPD)

- Sun-101/eflow® (glycopyrrolate) NDA is currently under review; if approved, it would represent the first available nebulized long-acting muscarinic...